The Role of Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles (MSC-EVs) in Normal and Abnormal Hematopoiesis and Their Therapeutic Potential

Overview

Journal J Clin Med

Specialty General Medicine

Date 2020 Apr 5

PMID 32245055

Citations 43

Authors

Aristea K Batsali

Anthie Georgopoulou

Irene Mavroudi

Angelos Matheakakis

Charalampos G Pontikoglou

Helen A Papadaki

Affiliations

Soon will be listed here.

Abstract

Mesenchymal stem cells (MSCs) represent a heterogeneous cellular population responsible for the support, maintenance, and regulation of normal hematopoietic stem cells (HSCs). In many hematological malignancies, however, MSCs are deregulated and may create an inhibitory microenvironment able to induce the disease initiation and/or progression. MSCs secrete soluble factors including extracellular vesicles (EVs), which may influence the bone marrow (BM) microenvironment via paracrine mechanisms. MSC-derived EVs (MSC-EVs) may even mimic the effects of MSCs from which they originate. Therefore, MSC-EVs contribute to the BM homeostasis but may also display multiple roles in the induction and maintenance of abnormal hematopoiesis. Compared to MSCs, MSC-EVs have been considered a more promising tool for therapeutic purposes including the prevention and treatment of Graft Versus Host Disease (GVHD) following allogenic HSC transplantation (HSCT). There are, however, still unanswered questions such as the molecular and cellular mechanisms associated with the supportive effect of MSC-EVs, the impact of the isolation, purification, large-scale production, storage conditions, MSC source, and donor characteristics on MSC-EV biological effects as well as the optimal dose and safety for clinical usage. This review summarizes the role of MSC-EVs in normal and malignant hematopoiesis and their potential contribution in treating GVHD.

Citing Articles

Exosome-based miRNA delivery: Transforming cancer treatment with mesenchymal stem cells.

Balaraman A, Babu M, Afzal M, Sanghvi G, M M R, Gupta S Regen Ther. 2025; 28:558-572.

PMID: 40034540 PMC: 11872554. DOI: 10.1016/j.reth.2025.01.019.

Expression of ABCB1, ABCC1, and LRP in Mesenchymal Stem Cells from Human Amniotic Fluid and Bone Marrow in Culture-Effects of In Vitro Osteogenic and Adipogenic Differentiation.

Romao C, de Lara Janz F, Ruiz J, Lopes M, Cristante A, de Barros Filho T Int J Mol Sci. 2025; 26(2).

PMID: 39859227 PMC: 11765172. DOI: 10.3390/ijms26020510.

Harnessing the power of exosomes for diagnosis, prognosis, and treatment of hematological malignancies.

Mohseni A, Salehi F, Rostami S, Hadiloo K, Hashemi M, Baridjavadi Z Stem Cell Res Ther. 2025; 16(1):6.

PMID: 39773361 PMC: 11708188. DOI: 10.1186/s13287-024-04125-0.

Somatic piRNA and PIWI-mediated post-transcriptional gene regulation in stem cells and disease.

Patel M, Jiang Y, Kakumani P Front Cell Dev Biol. 2024; 12:1495035.

PMID: 39717847 PMC: 11663942. DOI: 10.3389/fcell.2024.1495035.

Mesenchymal stem cell-derived extracellular vesicles for cell-free therapy of ocular diseases.

Liu X, Hu L, Liu F Extracell Vesicles Circ Nucl Acids. 2024; 3(2):102-117.

PMID: 39698446 PMC: 11648472. DOI: 10.20517/evcna.2022.08.

References

Castro-Manrreza M, Montesinos J . Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications. J Immunol Res. 2015; 2015:394917. PMC: 4417567. DOI: 10.1155/2015/394917. View

Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D . Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8(4):315-7. DOI: 10.1080/14653240600855905. View

Gnecchi M, Zhang Z, Ni A, Dzau V . Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res. 2008; 103(11):1204-19. PMC: 2667788. DOI: 10.1161/CIRCRESAHA.108.176826. View

Colombo M, Raposo G, Thery C . Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014; 30:255-89. DOI: 10.1146/annurev-cellbio-101512-122326. View

Zhang Y, Chopp M, Meng Y, Katakowski M, Xin H, Mahmood A . Effect of exosomes derived from multipluripotent mesenchymal stromal cells on functional recovery and neurovascular plasticity in rats after traumatic brain injury. J Neurosurg. 2015; 122(4):856-67. PMC: 4382456. DOI: 10.3171/2014.11.JNS14770. View

Kavanagh H, Mahon B . Allogeneic mesenchymal stem cells prevent allergic airway inflammation by inducing murine regulatory T cells. Allergy. 2010; 66(4):523-31. DOI: 10.1111/j.1398-9995.2010.02509.x. View

Kim H, Choi D, Yun S, Choi S, Kang J, Jung J . Proteomic analysis of microvesicles derived from human mesenchymal stem cells. J Proteome Res. 2011; 11(2):839-49. DOI: 10.1021/pr200682z. View

Schallmoser K, Bartmann C, Rohde E, Reinisch A, Kashofer K, Stadelmeyer E . Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells. Transfusion. 2007; 47(8):1436-46. DOI: 10.1111/j.1537-2995.2007.01220.x. View

Pavlaki K, Pontikoglou C, Demetriadou A, Batsali A, Damianaki A, Simantirakis E . Impaired proliferative potential of bone marrow mesenchymal stromal cells in patients with myelodysplastic syndromes is associated with abnormal WNT signaling pathway. Stem Cells Dev. 2014; 23(14):1568-81. DOI: 10.1089/scd.2013.0283. View

10.

Kumar B, Garcia M, Weng L, Jung X, Murakami J, Hu X . Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion. Leukemia. 2017; 32(3):575-587. PMC: 5843902. DOI: 10.1038/leu.2017.259. View

11.

Hashmi S, Ahmed M, Murad M, Litzow M, Adams R, Ball L . Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. Lancet Haematol. 2016; 3(1):e45-52. DOI: 10.1016/S2352-3026(15)00224-0. View

12.

Burnouf T, Strunk D, Koh M, Schallmoser K . Human platelet lysate: Replacing fetal bovine serum as a gold standard for human cell propagation?. Biomaterials. 2015; 76:371-87. DOI: 10.1016/j.biomaterials.2015.10.065. View

13.

Asari S, Itakura S, Ferreri K, Liu C, Kuroda Y, Kandeel F . Mesenchymal stem cells suppress B-cell terminal differentiation. Exp Hematol. 2009; 37(5):604-15. PMC: 2747661. DOI: 10.1016/j.exphem.2009.01.005. View

14.

Mulcahy L, Pink R, Carter D . Routes and mechanisms of extracellular vesicle uptake. J Extracell Vesicles. 2014; 3. PMC: 4122821. DOI: 10.3402/jev.v3.24641. View

15.

Kapoor S, Patel S, Kartan S, Axelrod D, Capitle E, Rameshwar P . Tolerance-like mediated suppression by mesenchymal stem cells in patients with dust mite allergy-induced asthma. J Allergy Clin Immunol. 2011; 129(4):1094-101. DOI: 10.1016/j.jaci.2011.10.048. View

16.

Kouvidi E, Stratigi A, Batsali A, Mavroudi I, Mastrodemou S, Ximeri M . Cytogenetic evaluation of mesenchymal stem/stromal cells from patients with myelodysplastic syndromes at different time-points during ex vivo expansion. Leuk Res. 2016; 43:24-32. DOI: 10.1016/j.leukres.2016.02.007. View

17.

Lim M, Pang Y, Ma S, Hao S, Shi H, Zheng Y . Altered mesenchymal niche cells impede generation of normal hematopoietic progenitor cells in leukemic bone marrow. Leukemia. 2015; 30(1):154-62. DOI: 10.1038/leu.2015.210. View

18.

Horwitz E, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini F . Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy. 2005; 7(5):393-5. DOI: 10.1080/14653240500319234. View

19.

Lee C, Mitsialis S, Aslam M, Vitali S, Vergadi E, Konstantinou G . Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension. Circulation. 2012; 126(22):2601-11. PMC: 3979353. DOI: 10.1161/CIRCULATIONAHA.112.114173. View

20.

FRIEDENSTEIN A, Gorskaja J, Kulagina N . Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol. 1976; 4(5):267-74. View